Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment

Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020

“…Rates of concomitant autoimmune diseases tend to be higher in type IIb [25,[118][119][120][121] Rates of concomitant allergic diseases might be higher in type I [119] Total IgE levels low in type IIb and normal or high in type I [14,25] Basopenia rates might be higher in type IIb [24, 111] 2 Eosinopenia rates tend to be higher in type IIb [122] C-reactive protein levels may be higher in type IIb [25,123] ANA positivity rates may be higher in type IIb [124] Responder rates to sgAHs may be lower in type IIb [122][123][124][125] Responder rates to omalizumab high in type I [28] and low in type IIb [62,122,126] Speed of response to omalizumab slow in type IIb [127] Immunosuppressive therapy can be effective in type IIb [128-134] 3 TPO, thyroperoxidase; TG, thyroglobulin; TF, tissue factor; IL, interleukin; dsDNA, double-stranded DNA; BHRA, basophil histamine release assay; BAT, basophil activation test; ASST, autologous serum skin test; WB, Western blot; ELISA, enzyme-linked immunosorbent assay; CRP, C-reactive protein; ANA, antinuclear antibodies; sgAHs, second-generation antihistamines. 1 Measured by ELISA or radioimmunoassay.…”

A protocol for the development and internal validation of a model to predict clinical response to antihistamines in urticaria patients

“…Step 1: Selection of variables for the model. The selection of the model's prognostic variables was made according to biological plausibility, an exhaustive review of the variables that have been previously studied [12,15,28,30,31,[34][35][36][37][38], and the feasibility of their measurement in clinical practice (Table 1).…”

“…Despite the increased knowledge of its pathogenesis, the evolution of this disease in each patient is currently uncertain. Different studies have reviewed several clinical and laboratory markers to predict the evolution of the disease in terms of its duration or clinical treatment response [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16].…”

Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies

“…12 Eosinophil infiltration in the skin is a key feature of several chronic pruritic skin diseases such as CSU. 92,147 For example, MBP and EPO levels are increased in lesions of patients with chronic urticaria, 12,147 and ECP serum levels and disease activity are linked in this disease. 130 Patients with AD exhibit elevated serum levels of MBP, EDN, and ECP, which correlate with disease activity (Table III).…”